Executive interview – Silence Therapeutics

Published on 18 July 2019
 

In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.

Share this with friends and colleagues

You may also be interested in these

Fund manager interview – UIL

Investment companies
10 December 2019

Executive interview – PIERER Mobility at EKF 2019

Industrials
9 December 2019

Executive interview – mVISE at EKF 2019

TMT
9 December 2019

Executive interview – paragon at EKF 2019

Industrials
9 December 2019

Cookies

This site uses cookies: Find out more.